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CLL cells are resistant to smac mimetics because
of an inability to form a ripoptosome complex
C Maas1,2,6, JM Tromp1,2,6, J van Laar1,2, R Thijssen1,2, JA Elias1,2, A Malara2, A Krippner-Heidenreich3, J Silke4, MHJ van Oers1,5
and E Eldering*,2,5
In the lymph node (LN) environment, chronic lymphocytic leukemia (CLL) cells display increased NF-jB activity compared with
peripheral blood CLL cells, which contributes to chemoresistance. Antagonists of cellular inhibitor of apoptosis proteins (cIAPs)
can induce apoptosis in various cancer cells in a tumor necrosis factor-a (TNFa)-dependent manner and are in preclinical
development. Smac-mimetics promote degradation of cIAP1 and cIAP2, which results in TNFR-mediated apoptosis via formation
of a ripoptosome complex, comprising RIPK1, Fas-associated protein with death domain, FLICE-like inhibitory protein and
caspase-8. CD40 stimulation of CLL cells in vitro is used as a model to mimic the LN microenvironment and results in NF-jB
activation and TNFa production. In this study, we investigated the response of CLL cells to smac-mimetics in the context of CD40
stimulation. We found that treatment with smac-mimetics results in cIAP1 and cIAP2 degradation, yet although TNFa is
produced, this did not induce apoptosis. Despite the presence of all components, the ripoptosome complex did not form upon
smac-mimetic treatment in CLL cells. Thus, CLL cells seem to possess aberrant upstream NF-jB regulation that prevents
ripoptosome formation upon IAP degradation. Unraveling the exact molecular mechanisms of disturbed ripoptosome formation
may offer novel targets for treatment in CLL.
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Chronic lymphocytic leukemia (CLL) is characterized by an
accumulation of CD5þ monoclonal B lymphocytes and is the
most common leukemia in the western world.1 A cure for CLL
is not yet available, as relapses eventually occur from chemo-
resistant sites such as the lymph nodes (LNs). CD40 ligand
(CD40L) presented by CD4þ T cells in the LN enhances
survival of CLL cells and is an important cause of chemother-
apy resistance.2 The CD40 signaling pathway activates the
nuclear factor kappa B (NF-kB) pathway causing a decrease
in pro-apoptotic and increase in anti-apoptotic Bcl-2 proteins
rendering cells resistant to apoptosis.3,4 From the LNs, CLL
cells translocate to the peripheral blood (PB), where they
arrest in G0/G1 of the cell cycle and accumulate because of a
failure to undergo apoptosis.5 New therapeutic strategies are
needed to overrule LN pro-survival signals and circumvent
apoptosis blockades.
The inhibitor of apoptosis proteins (IAPs) are important
regulators of apoptosis. The IAP family consists of eight
proteins and includes X-linked IAP (XIAP) and cellular
inhibitor of apoptosis protein (cIAP1) and cIAP2.6–9 IAPs are
characterized by the presence of one to three baculovirus
inhibitor of apoptosis repeat (BIR) domains, a 70–80-amino-
acid-long protein interaction domain.10,11 XIAP is upregulated
in many cancers and binds and inhibits caspases via its BIR2
and BIR3 domains. Smac/Diablo is a natural BIR-binding
antagonist of IAPs that is released from the damaged
mitochondria. To overcome overexpressed XIAP and render
cancers more susceptible to chemotherapy, small-molecule
inhibitors based on the smac/BIR interaction motif were
developed and are now called smac-mimetics. In addition to
inhibiting XIAP, most smac-mimetics were found to promote
the proteasomal degradation of cIAP1/2.12–15
cIAP1 and 2 can bind with low affinity to caspases but do not
inhibit them directly. Rather, it appears IAPs indirectly prevent
caspase activation.16–18 For example, during tumor necrosis
factor-a (TNF)/TNF receptor 1 (TNFR1) signaling, cIAP1 and
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2 are required to mediate the K63 and K11 ubiquitination of
receptor-interacting protein kinase 1 (RIPK1) in the mem-
brane-bound signaling complex. This provides docking sites
for different kinases and activates the canonical NF-kB
signaling pathway.15,19–21 Canonical NF-kB drives FLICE-
like inhibitory protein (cFLIP) transcription, thereby limiting
caspase-8 activity. Furthermore, cIAP1/2 limits the accumula-
tion of RIPK1 in the downstream cytosolic complex 2 by K48
ubiquitylation. In the absence of cIAPs, cFLIP transcription is
reduced and RIPK1 levels are increased, thus shifting the
signaling to cell death. Furthermore, smac-mimetics appear to
prime cells, as intracellular RIPK1-containing complexes
accumulate in the absence of an exogenous stimulus. This
intracellular complex, comprising Fas-associated protein with
death domain (FADD), caspase-8 and cFLIP, has been called
the ripoptosome and is most likely related to the secondary
cytosolic complex that assembles post-TNF treatment.22–24
cIAP1 and 2 also act as negative regulators of the alternative
or non-canonical NF-kB signaling pathway, by K48 ubiquity-
lating the upstream regulator NF-kB-inducing kinase
(NIK).15,20 In the absence of cIAPs, NIK levels rise, promoting
its auto-activation and downstream activation of IkB kinase 1,
processing of NF-kB2 p100 and nuclear translocation of NF-
kB2 p52. In some cells, the activation of NF-kB in this manner
can promote the production of TNF.15,20 Thus, in some cancer
cells, smac-mimetics can simultaneously promote production
of TNF and sensitize cells to the cytotoxic activity of TNF. In
other cells where TNF is not produced, many cells are
sensitized to exogenously added TNF.
In CLL, relapses have been proposed to originate from the
protective LN and bone marrow microenvironment, where
cells receive pro-survival signals, among others from TNF-
family member CD40L. CIAP1/2 are required for NF-kB
activation in response to different TNF-family members,
including CD40L25 and prevent ripoptosome formation.
Therefore, targeting cIAP1/2 with smac-mimetics could be
an attractive way to overcome CLL chemoresistance.
The aim of this study was to investigate the various
adaptor proteins of the intracellular TNFR signalosome and
ripoptosome in CD40-stimulated CLL cells. We explored
whether smac-mimetics could mediate the degradation of
cIAP1 and 2 and induce (TNFa-dependent) cell death alone
or in combination with death receptor ligands. We found that
although CLL cells express all proteins required for an
effective cell death response to smac-mimetics, CLL cells
were resistant to smac-mimetic-induced cell death.
We hypothesize that this resistance may be linked to the
rapid recurrence of cIAP2.
Results
CD40 stimulation of CLL cells induces non-canonical
NF-jB activation and production of TNFa and its
receptors TNFR1 and TNFR2. Activation of the non-
canonical pathway, the subsequent production of TNFa and
autocrine activation of TNFR1 and/or TNFR2 have been
reported to be essential for smac mimetic-induced cell death
in various cell types.14,15 We have previously shown that
prolonged CD40 stimulation induces the activation of the
non-canonical NF-kB signaling pathway in CLL cells,
following the activation of the canonical NF-kB signaling
pathway.4 In agreement with our earlier report, we observed
stabilization of NIK, phosphorylation of IkBa and the
conversion of the p100 pro-form into the active NF-kB
subunit p52 in patient CLL cells stimulated with CD40L
(Figure 1a). The presence of cIAPs and RIPK1 in target
cells is essential for the induction of cell death by smac-
mimetics, because smac-mimetics target IAPs specifically
while RIPK1 knockout cells are resistant to smac-mimetic-
induced cell death.14,15,26 In line with a previous study,27
cIAP1 and 2 are both present in unstimulated PB CLL cells.
Although the levels of cIAP1 and cIAP2 were unaffected by
CD40 stimulation, TNF receptor-associated factor 2
(TRAF2) and RIPK1 levels were markedly enhanced (lane
3, Figure 1b). In line with previous studies,4,14,15 activation
of non-canonical NF-kB was accompanied by the secretion
of TNFa (Figure 1c). Cell-surface TNFR1 and TNFR2
expression measured by antibody staining and flow cyto-
metry were also both significantly upregulated upon CD40
stimulation (Figure 1d).
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Figure 1 Patient CLL cells stimulated with CD40L activate the non-canonical
NF-kB pathway and the production of TNF, TNFR1 and TNFR2. (a) CLL cells were
not cultured ( ) or co-cultured for 48 h with 3T3 control feeder layer cells (3T3) or
on CD40L-expressing 3T3 feeder layer cells (3T40) for 48 h. Lysates separated on
SDS-PAGE gels and western blotted with the indicated antibodies, where actin was
served as a loading control. Results of one representative CLL patient, of a total of
nine analyzed, are shown. (b) CLL cells were treated as in a. Protein levels of cIAP1,
cIAP2, TRAF2, TRAF6 and RIPK1 were analyzed by immunoblotting on total
lysates. Blots from one representative CLL patient, of a total of three analyzed, are
shown. (c) CLL cells were co-cultured with 3T3 or 3T40 cells for 72 h, after which
supernatants were collected and TNFa levels were measured using ELISA.
The means and S.E.M. of n¼ 16 independent CLL samples are represented.
(d) Expression levels of TNFR1 and TNFR2 were measured by flow cytometry of
freshly isolated, 3T3 and 3T40 co-cultured CLL cells (n¼ 8, independent CLL
samples). Error bars represent S.E.M. Asterisks indicate statistical significance:
*0.01oPo0.05 and **0.001oPo0.01
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The smac-mimetic Compound A promotes proteasomal
degradation of cIAP1 and cIAP2 but does not increase
activation of non-canonical NF-jB in CD40-stimulated
CLL cells. Our data showed that CD40 stimulation of
primary patient CLL cells resulted in activation of the non-
canonical NF-kB signaling pathway, TNFa secretion and
upregulation of surface TNFR1 and TNFR2 expression,
indicating that smac-mimetics might be effective in interfering
with TNFa/NFkB signaling in CLL cells.
We therefore investigated the effect of the bivalent smac-
mimetic Compound A15,28 on cIAP1 and cIAP2 levels and on
the activation of NF-kB. In agreement with earlier RNA
studies,29 we observed using western blotting (Figure 2a) that
CLL cells express low levels of cIAP1. The cIAP1 present
rapidly disappeared with Compound A treatment. cIAP2 was
expressed at readily detectable levels, which also quickly
disappeared with Compound A, consistent with other
studies,28,30 and partially recovered after 4 h of treatment
(Figure 2a). Bivalent smac-mimetics, such as Compound A,
have been shown to induce cIAP1/2 degradation by promoting
their proteasomal degradation.15,28,30 Alternatively, cIAPs
can also reportedly be degraded via the lysosome, upon
stimulation with TNF-family member TNF-related weak
inducer of apoptosis (TWEAK),31 or compound A might block
cIAP expression. We found that the proteasomal inhbitor
MG132, but not the translation inhibitor cycloheximide (CHX)
or a combination of reagents that block lysosomal activity,
blocked the effects of Compound A (Figure 2b). This
demonstrates that cIAP2 degradation occurs via the protea-
some also in CLL cells. We have previously shown that p65
activity correlates with expression of the Bcl-2-related protein
A1 (Bfl-1), whereas that of p52 correlates with B-cell
lymphoma extra large (Bcl-XL) expression.4 Therefore, to
assess the effect of Compound A on the activation of these
two NF-kB subunits, we analyzed their DNA-binding activity
on the promoters of these target genes. Consistent with the
earlier studies,4 CD40L stimulation enhanced both p65 and
p52 DNA-binding activity to their respective promoters
(Figure 2c) and increased expression of Bfl-1 and Bcl-XL
expression (Figure 2d). Compound A treatment activated both
the pathways modestly in unstimulated cells, with a more
marked increase in the p52/non-canonical pathway. In case of
CD40-stimulated cells, compound A decreased p65- and p52-
binding activity, Bcl-XL and Bfl-1 expression, and also TNFa
secretion somewhat, but these effects did not reach statistical
significance (Figures 2c–e).
CLL cells are resistant to smac mimetic-mediated cell
death. Our results suggested that the CLL cells could be
sensitive to cell death induced by smac-mimetic and
particularly sensitive to combined CD40L and smac-mimetic
treatment, in view of the enhanced NF-kB signaling and
TNFa production. Remarkably, however, not only unstimu-
lated CLL cells but also CD40-stimulated CLL cells were
insensitive to Compound A (Figures 3a and b, left panel).
This was tested for420 CLL samples in order to investigate
whether (prognostic) subgroups might be sensitive,
but this turned out not to be the case (see also Table 1
for patient characteristics). Only the highest dose of
Compound A applied (500 nM) induced apoptosis in some
CD40-stimulated CLL samples (Figure 3a). Moreover, both
unstimulated and CD40-stimulated CLL cells were also
unresponsive to a second bivalent smac-mimetic, smac-
mimetic 83 (SM83) (Figure 3b, right panel).32 As a control,
the sensitive rhabdymyosarcoma cell line Kym-115 was
treated with increasing concentrations of Compound A or
SM83, which resulted in high levels of apoptosis already at
1 nM (Figure 3b). The slight increase in apoptosis induced by
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Figure 2 The effect of CD40 stimulation and Compound A treatment on cIAP
levels, NF-kB activity and target gene expression. (a) CLL cells were co-cultured
with 3T3 cells (left) or 3T40 cells (right) in the presence of Compound A (250 nM) for
1, 4 and 24 h. Immunoblotting was performed for cIAP1 and cIAP2 on total lysates,
and actin was used as a loading control. Blots from a representative CLL patient, of
a total of three (left) or 4 (right), are shown. (b) CLL cells co-cultured with 3T40 cells
were treated for 4 h with the indicated compounds in the following concentrations:
Compound A 250 nM, CHX 20mg/ml, MG132 500 nM, bafilomycin A 100 nM and
ammonium chloride 25mM. Immunoblotting was performed for cIAP2 on total
lysates, and actin was used as a loading control. Blots are representative of two CLL
patients. Patient samples used were nos. 39 and 40 from Table 1. (c) CLL cells were
co-cultured with 3T3 or 3T40 cells in the presence or absence of Compound A
(250 nM) for 24 h. Activity of the NF-kB subunits p65 and p52, as a measure of
activity of the canonical and non-canonical NF-kB pathways respectively, was
determined using ELISA with the TransAM NFkB family transcription factor assay
kit (n¼ 3). Error bars represent S.E.M. (d) CLL cells were treated as in c, but for
48 h. Bcl-XL and Bfl-1 mRNA expression levels were analyzed by RT-MLPA (n¼ 5),
and depicted as percentage of the total signal in that sample. b-Glucuronidase is
depicted as a housekeeping gene not responsive to NFkB. Error bars present
S.E.M. (e) CLL cells were treated as in c, but for 72 h. Supernatants were collected,
and TNFa levels were measured using ELISA (n¼ 16). Error bars represent S.E.M.
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500 nM Compound A in CD40-stimulated CLL cells could not
be blocked by anti-TNFa, suggesting that this process was
TNFa independent. In addition, and consistent with the fact
that TNFa is already produced by CD40L-stimulated cells, no
significant increase in apoptosis of CD40-stimulated CLL
cells was observed when exogenous TNFa was combined
with Compound A (Figure 3c). Several studies have shown
that smac-mimetics can sensitize different types of cancer
cells to apoptosis induction by TNF superfamily members
Fas ligand (FasL/CD95L/TNFSF6) and TNF-related apopto-
sis inducing ligand (TRAIL) (TNFSF10).23,32–37 However, we
did not observe synergistic effects in CLL cells (Figure 3d).
The pro-apoptotic activity of FasL and TRAIL was verified
with Jurkat T cells, which readily underwent apoptosis upon
exposure to TRAIL and FasL (data not shown). CD40L
stimulation enhanced the expression of anti-apoptotic Bcl-2
proteins, which could contribute to Compound A resistance
(Figure 2d). We therefore specifically inhibited Bcl-2 and
Bcl-XL with the compound ABT-737 to assess this
possibility, using concentrations of ABT-737 that induce
modest apoptosis in CD40-stimulated CLL cells.2,38 How-
ever, CD40-stimulated CLL cells could not be sensitized to
Compound A with ABT-737, indicating that induction of pro-
survival Bcl-2 family members by CD40 stimulation does not
mediate resistance to Compound A in CLL cells (Figure 3e).
In addition, no synergistic effects of Compound A with a
range of cytotoxic drugs, such as fludarabine, proteasome
inhibitor bortezomib, HDAC inhibitors suberohydroxamic acid
(SBHA) and trichostatin A, syk inhibitors R406 and picea-
tannol, Src/Abl inhibitor dasatinib or NF-kB inhibitor Bay were
observed for CLL cells (data not shown).
Primary CLL cells are resistant to combination treatment
with Compound A and TNFR1/2-specific TNFa mutants.
In contrast to TNFR1, TNFR2 does not contain a death
domain and can only activate NF-kB.39–42 On average, we
observed a strong increase in TNFR2 levels and a moderate
enhancement of TNFR1 levels in CLL cells upon CD40
stimulation. Thus, potentially, TNFR2 could sequester the
TNFa produced in CD40-stimulated cells and thereby
antagonize pro-death TNF/TNFR1 signaling. To study this
possibility, we treated CLL cells with TNFR1- and TNFR2-
selective TNFa mutants (TNFa-TNFR1 and TNFa-TNFR2,
respectively), in combination with Compound A. Two patient
samples were studied, one with relatively high levels of
TNFR2 (patient 38 from Table 1) and one with relatively
high levels of TNFR1 (patient 18), in CD40-stimulated cells
(Figure 4a). Pt-38 resembled the majority of patients
(as depicted in Figure 1d). In both samples, combination
treatment with Compound A and TNFa-TNFR1 did not
induce apoptosis in unstimulated nor in CD40-stimulated
CLL cells (Figures 4b and c). Decoy TNFR agent
Etanercept was added to prevent TNFR2 signaling from
TNFa produced by CD40-stimulated CLL cells, but again no
differences in apoptosis were observed (Figure 4c).
We measured whether expression of Fas receptor
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Figure 3 The effects of smac mimetics, alone or in combination with death receptor ligands or ABT-737, on apoptosis in unstimulated and CD40-stimulated CLL cells.
(a) CLL cells were co-cultured with 3T3 (n¼ 13) or 3T40 cells (n¼ 26) for 72 h in the presence or absence of the indicated concentrations of Compound A. Apoptosis levels
were measured with annexin V/PI staining, and averaged data are shown. Patient characteristics are summarized in Table 1. For 3T3 conditions nos. 1, 3, 5, 7–9, 13, 23–26,
28 and 29 were used, and for 3T40 conditions nos 1, 2, 4–7, 9–15 and 18–30 were used. (b) CLL cells co-cultured with 3T3 (n¼ 4) or 3T40 cells (n¼ 4) were treated for 48 h
with the indicated concentrations of Compound A or SM83. The rhabdomyosarcoma cell line Kym-1, known to be sensitive to treatment with smac mimetics was used as a
positive control and was treated with the same concentrations for 24 h. Apoptosis was analyzed by DioC6/PI staining. Error bars represent S.D. Patient samples used were
nos. 31, 32, 33 and 35 from Table 1. (c) CLL cells co-cultured with 3T40 cells were treated with Compound A (250 nM) or recombinant TNFa (5 mg/ml) alone or together, or a
combination of Compound A and TNFR1/2 blocking reagent Etanercept (10 mg/ml; indicated as TNFa) for 72 h (n¼ 4). Apoptosis was measured by annexin V/PI staining.
Error bars represent S.E.M. and ‘***’ indicates a statistical significance of Po0.001. Patient samples used were nos. 1,2,12 and 18 from Table 1. (d) CLL cells co-cultured with
3T40 cells were treated with a combination of Compound A (250 nM) and FasL (10 or TRAIL (100 ng/ml) for 48 h (n¼ 3), and apoptosis was determined by annexin V/PI
staining. Error bars represent S.E.M. and ‘**’ indicates a statistical significance of 0.001oPo0.01. (e) CLL cells co-cultured with 3T40 cells were treated with a combination of
Compound A (1–500 nM) and ABT-737 (100 nM) for 48 h (n¼ 3), and apoptosis was determined by DioC6/PI staining. Error bars represent S.E.M. Patient samples used were
nos. 31, 39 and 40 from Table 1
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increased43 in response to the TNFR stimulation. Especially,
in pt-18, we observed an increase of Fas expression upon
addition of both TNFa variants, verifying that they were active
(Figure 4d).
CLL cells are unable to form the ripoptosome upon
treatment with Compound A. In TNF-stimulated cells, the
absence of cIAPs induces the formation of a cytosolic
complex 2 with more RIPK1. Increased levels of death
domain-containing RIPK1 are able to recruit and drive
activation of caspase-8-causing apoptosis, or if caspase-8
activity is limiting, auto-activate and thereby phosphorylate
RIPK3 and cause necroptosis. This complex is probably
identical with the ripoptosome complex that can form in the
Table 1 Patient characteristics
ID
no.
Age Rai
stage
%CD5
CD19a
IgVHb Chromosomal
aberrationsc
Previous
therapy
P53d
1 76 1 95.7 M Del 11q22 None F
2 50 1 90 UM Trisomy 12 None F
3 63 2 89.6 M None None F
4 52 0 86.2 UM Trisomy 12 None F
5 66 0 86.2 UM ND None F
6 72 0 99.8 M ND None F
7 49 3 99.7 M ND None F
8 74 0 96.2 M Del 13q14 None F
9 53 2 81.8 UM Del 17p13 Clb, FCO F
10 69 1 86.8 UM ND FCR F
11 41 2 89 M Del 13q14 Clb, F F
12 66 0 99.5 UM ND None F
13 61 1 99.7 M ND None F
14 76 ND 99.1 M ND ND F
15 56 ND 99.3 M ND ND F
16 60 ND 98.8 M ND ND F
17 63 2 89.6 M None Clb F
18 74 2 92.5 M ND Clb F
19 59 4 100 M ND None F
20 73 2 98.4 UM ND None F
21 55 ND 93.8 M ND ND F
22 59 2 92.3 UM Del 11q22 Clb F
23 81 ND 93.3 M ND ND F
24 60 0 99.2 UM ND None F
25 75 0 94.6 M ND ND F
26 51 2 79.9 UM Del 13q14 Clb F
27 53 4 82.1 UM Del 11q22 Clb, R-CHOP F
28 63 1 96.9 M None None F
29 83 2 96.5 M ND None F
30 47 0 87.5 M Del 13q14 None F
31 86 2 81 M Del 13q14 None F
32 68 ND 84.9 UM None None F
33 73 2 98.4 UM ND None F
34 61 ND 99.7 UM ND ND F
35 74 ND 74.5 ND None Clb F
36 55 ND 95.1 UM None None F
37 41 ND 56.4 UM Del 17p13 CVP, FCR,
alemtuzumab,
R-CHOP
D
38 66 4 96.6 M Del 13q14 Clb F
39 75 ND 82.9 M ND ND ND
40 73 ND 96.4 UM ND ND ND
Abbreviations: Clb, chlorambucil; F, fludarabine; FCO, fludarabine, cyclopho-
sphamide, ofatumumab; FCR, fludarabine, cyclophosphamide, rituximab;
ND, not determined; R-CHOP, rituximab, cyclophosphamide, doxorubicin,
vincristine, prednisone.
aPercentage of cells positive for CD5/CD19 surface expression measured by
FACS analysis.
bMutated IgVH gene (þ ) denotes 42% mutations compared with germline
sequence.
cAs determined by FISH. Probes for 11q22.3 (ATM), centromere 12 (CEP12),
13q14 (D13S319), 14q32 (IGH) and 17p13 (TP53) were obtained from Abbot-
Vysis. Samples with410% aberrant signals were considered abnormal.
dP53 functional status was measured via radiation-induced RNA expression of
p53 target genes Puma and Bax as described previously F¼p53 Functional,
D¼p53 Dysfunctional.
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Figure 4 The effects of Compound A in combination with specific TNFR1/2
stimulation in CLL cells. CLL cells of a representative patient, which
upregulate TNFR2 in response to CD40 stimulation (Pt-38 from Table 1), and
cells of a patient that upregulate TNFR1 rather than TNFR2 (Pt-18 from
Table 1) were selected for treatment with Compound A in combination with
specific TNFR1/2 agonistic antibodies. (a) TNFR1 and TNFR2 expression
levels on CLL cells of Pt-1 and Pt-2 co-cultured with control or 3T40-
expressing 3T3 cells as measured with antibody staining, using flow
cytometry. (b) CLL cells of Pt-1 and Pt-2 co-cultured with control 3T3 cells
were treated with Compound A (50–500 nM) alone or in combination with
TNFa mutants (100 ng/ml) that preferentially bind to TNFR1 (TNFa-TNFR1) or
TNFR2 (TNFa-TNFR2). (c) CLL cells of Pt-1 and Pt-2 co-cultured with 3T40
cells were treated with Compound A (50–500 nM) alone or in combination with
TNFa-TNFR1 (1 mg/ml) or TNFa-TNFR2 (1 mg/ml). Etanercept (10 mg/ml) was
added to block endogenous TNFa activity. (d) Percentage of Fas expression in
CLL cells co-cultured with 3T3 cells, in the presence and absence of TNFa-TNFR1
(1mg/ml) and TNFa-TNFR2 (1 mg/ml), as measured with antibody staining using
flow cytometry
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absence of ligand stimulation but which can be augmented
by diverse stimuli, including Fas, TRAIL, TLR ligands and
DNA damage.22–24 To study whether CLL cells are able to
form such a ripoptosome complex following cIAP1/2
degradation, we performed a caspase-8 immunoprecipita-
tion (IP) with control and Compound A-treated cells and
immunoblotted for RIPK1 and FADD.14 In Compound
A-sensitive Kym-1 cells, we were readily able to detect
such a complex 2/ripoptosome. In contrast, both in CD40L-
stimulated (Figures 5a and b, right panels) and unstimu-
lated CLL cells (Figure 5c), RIPK1 and FADD did not
co-immunoprecipitate with caspase-8, indicating that CLL
cells are unable to form the complex in response to
Compound A. Different cFLIP isoforms have been reported
to regulate the formation of the ripoptosome. The long
cFLIP isoform, cFLIPL, represses the formation of the
ripoptosome, whereas the short isoform, cFLIPS, promotes
ripoptosome assembly.22,23 Incorporation of cFLIPL into
the ripoptosome could thus be a cause of Compound A
resistance in CLL cells. However, we found that Kym-1
incorporated cFLIPL into the ripoptosome, whereas CLL
cells did not incorporate either form of FLIP (Figure 5b),
excluding this as a possible explanation for the lack of
response to smac mimetics.
Discussion
We show that CLL cells express all the components required
for ripoptosome/complex 2 formation in response to smac-
mimetic treatment, and that CD40 stimulation further
enhances the levels of TNFR1, TRAF2 and RIPK1. Yet,
despite the fact that smac-mimetics do induce the degradation
of cIAP1/2 in CLL cells, they are resistant to smac-mimetic-
induced cell death.
As we previously observed,4 CD40 stimulation activated the
canonical and non-canonical NF-kB signaling pathways. CLL
cells express cIAP1, cIAP2, TRAF2, RIPK1, caspase-8 and
FADD, and CD40 stimulation further enhanced the levels of
TRAF2 and RIPK1. Furthermore, CD40 stimulation mediated
TNFa production and upregulation of TNFa receptors TNFR1
and TNFR2. This suggested that CD40-stimulated CLL cells
might be particularly sensitive to smac mimetic treatment.
However, although cIAP1 and cIAP2 are degraded via the
proteasome in response to smac mimetic Compound A, CLL
cells are resistant to cell death induction by Compound A15
and a second smac mimetic, SM83.32 Both agents were
functional, as they could efficiently kill the rhabdymyosarcoma
Kym-1 cell-line.15 Compound A was also ineffective in
killing CLL cells in combination with TNFa, FasL or TRAIL.
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Figure 5 CLL cells are unable to form the ripoptosome in response to Compound A. (a–c) IP of caspase-8 in Kym-1 and CLL cells co-cultured with 3T40 cells (a and b) or
not (c) (numbers refer to CLL cases in Table 1), untreated or treated with Compound A, followed by detection of ripoptosome components caspase-8, RIP-1, FADD and
cFLIPL. CLL cells were co-cultured on 3T40 cells for 96 h, collected and treated with 100 nM Compound A for 4 h (a) or 24 h (b) or directly treated with 500 nM Compound A for
4 h (c). Kym-1 cells were exposed to 20 nM Compound A for 4 h. Caspase-8 IP was performed from total lysates. (a) Pre-IP, post-IP and IP samples were prepared, and
western blotting was performed for caspase-8 and RIPK1. Actin serves as a loading control. (b) Pre-IP and IP samples were prepared, and western blotting was performed for
caspase-8, RIPK1, FADD and cFLIPL. Actin serves as a loading control. *marks an aspecific band. (c) Pre-IP and IP samples were prepared, and western blotting was
performed for caspase-8 and RIPK1. Actin serves as a loading control
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Previously, it was found that XIAP inhibitors can synergisti-
cally kill primary CLL cells when combined with FasL or
TRAIL.37,44 Surprisingly, therefore, selective smac-mimetics
seem to be less effective than pan-IAP inhibitors, when
combined with death receptor ligands in CLL cells.
We explored several possible explanations for the resis-
tance of CLL cells to cell death induction by smac mimetics.
First, we observed that cIAP2 levels recovered during
treatment. This phenomenon has been previously described
by Petersen et al.45 in lung carcinoma cell lines and by
Darding et al.30 in colon carcinoma and melanoma cell lines.
Cell lines that were resistant to smac mimetics showed initial
degradation of cIAP2, but levels were restored after 3 h of
treatment.30,45 cIAP2 is a well-known NF-kB target, and we
therefore anticipated that its recovery was the cause of smac
mimetic-mediated NF-kB activation.30,45 Yet, general
NF-kB activity and TNF production was unaffected by
Compound A in CD40-stimulated CLL cells. Because NF-kB
activity encompasses a number of potential heteromeric
transcription factors, we also examined p65- and p52-specific
DNA-binding and expression of their respective target genes
Bfl-1 and Bcl-XL, but these were also undisturbed by
Compound A treatment. Next to NF-kB, phospho-inositide 3
kinase (PI3K) signaling can also regulate cIAP2 levels. In the
study of Petersen et al.,45 cIAP2 recovery upon smac mimetic
treatment could be suppressed with PI3K inhibitor LY294002,
which abrogated resistance to smac mimetics. In our hands,
LY294002 did not sensitize unstimulated nor CD40-stimulated
CLL cells to Compound A (data not shown). Thus, NF-kB and
PI3K do not appear to have a role in the cIAP2 reexpression in
CLL cells.
Second, we studied whether CD40L-mediated Bcl-XL
upregulation might contribute to Compound A resistance in
CD40L-stimulated CLL cells. ABT-737, which specifically
inhibits Bcl-XL and its close relative Bcl-2, could not sensitize
to Compound A, arguing against a contribution of increased
levels of Bcl-XL in resistance against smac mimetics.
Third, we investigated whether enhanced production of
TNFR2, which we observed after CD40 stimulation, was the
cause of resistance. As TNFR2 lacks a death domain and
hence cannot induce cell death,39–42 it could potentially
sequester the TNFa produced in response to CD40L, and
thus act as a decoy receptor. However, Compound A
combined with a TNFR1-selective TNFa mutant (TNFa-
TNFR1) did not induce cell death, not even in CLL cells with
relatively high TNFR1 levels and low TNFR2 levels. As
expected, the combination with a TNFR2-selective TNFa
mutant (TNFa-TNFR2) was also not effective.
Fourth, we assessed a role for cFLIPL. CFLIP isoforms
cFLIPS and cFLIPL have been reported to regulate the activity
of the ripoptosome.23 Although cFLIPS promotes ripoptosome
formation, cFLIPL represses the formation of the ripoptosome.
cFLIPL does so by forming a heterodimer with caspase-8,
which cleaves RIPK1 and RIP3.22,46 We therefore reasoned
that CLL cells might incorporate enhanced levels of cFLIPL in
its ripoptosome and prevent induction of cell death. IP of
caspase-8 showed that the ripoptosome formed in Kym-1
cells upon treatment with Compound A. Unexpectedly,
although Kym-1 cells are exquisitely sensitive to Compound
A, cFLIPL was nevertheless found to be incorporated in the
complex. Kym-1 is a rather unique rhabdomyosarcoma cell
line that is particularly sensitive to the cytotoxic activity of
autocrine TNF induced when they are treated with TWEAK,
CD40L, CD30L and even by TNFR2 stimulation alone.31,47,48
Thus, we speculate that this is a question of a low threshold for
cell death and can therefore still be induced by a complex
2/ripoptosome in the presence of cFLIPL. In contrast, both
unexposed and CD40L-exposed CLL cells failed to form the
complex in response to high Compound A dosages. We could
not detect any RIPK1, FADD or cFLIPL immunoprecipitating
with caspase-8. Thus, cFLIPL does not have a role in CLL
resistance to smac mimetics. Rather, the ripoptosome
complex is not formed at all.
Finally, defective ripoptosome formation might derive from
aberrant upstream NF-kB regulation. Cylindromatosis protein
(CYLD) regulates ripoptosome formation by deubiquitinating
enzyme RIPK1.49 In the absence of CYLD, RIPK1 is no longer
deubiquitinated and thus is prevented from translocating to
the ripoptosome. Lymphoid enhancer-binding factor 1 (LEF1)
has been identified as a transcriptional repressor of CYLD.50
Compared with healthy B cells, CLL cells were reported to
express relatively high levels of LEF1 and low levels of CYLD,
causing resistance to TNFa-induced necroptosis.50 High
LEF1 and low CYLD levels in CLL cells could in theory also
explain CLL inability to form the ripoptosome. However, in five
samples tested, we did not observe a negative correlation
between LEF1 and CYLD levels in CLL (results not shown)
and found no indication that this might be the cause.
In conclusion, we show that CD40 stimulation of CLL cells
mediates the activation of the canonical and non-canonical
NF-kB pathways, TNFa production and upregulation of both
TNFR1 and TNFR2. Although unstimulated and CD40-
stimulated CLL cells respond to smac mimetic treatment by
degrading cIAP1 and cIAP2 via the proteasome, they are
unable to form the ripoptosome and die via apoptosis or
necroptosis. We have excluded decoy receptor activity of
TNFR2, increased levels of Bcl-XL, cFLIPL inhibition of the
ripoptosome and a possible contribution of CYLD as causal
factors in smac mimetic resistance in CLL cells. Most likely,
rapid recovery of cIAP2 levels during treatment contributes to
the resistance. Further elucidation of the molecular mechan-
ism of disturbed ripoptosome formation may offer novel
therapeutic targets for CLL.
Materials and Methods
Patient material. After informed consent, patient material was obtained
during diagnostic or follow-up procedures at the departments of Hematology and
Pathology of the Academic Medical Center, Amsterdam. This study was approved
by the AMC Ethical Review Board and conducted in agreement with the Helsinki
Declaration of 1975, revised in 1983. PB mononuclear cells of patients with CLL
obtained after Ficoll density gradient centrifugation (Pharmacia Biotech,
Roosendaal, The Netherlands) were frozen and stored as described.2 Expression
of CD5 and CD19 (both purchased from Beckton Dickinson (BD) Biosciences, San
Jose, CA, USA) on leukemic cells was assessed by flow cytometry (FACScalibur;
BD Biosciences) and analyzed with CellQuest software (BD Biosciences). Patient
characteristics are reported in Table 1.
Reagents. Compound A was obtained under MTA from TetraLogic Pharma-
ceuticals (Malvern, PA, USA) and was dissolved in dimethyl sulfoxide (DMSO).
SM8332 was kindly provided by Dr. D Lecis and Dr. D Delia (Department of
Experimental Oncology, Fondazione IRCCS Instituto Nazionale Tumori, Milano,
Italy). ABT-737 was obtained from Abbott (Abbott Park, Green Oaks, IL, USA).2,38
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SuperKiller TRAIL was purchased from Alexis Biochemicals (San Diego, CA,
USA). TNFa-blocking reagent (Etanercept) was obtained from Pfizer (Kent, UK).
Recombinant human TNFa was obtained from Invitrogen (Carlsbad, CA, USA).
TNFR1 (FITC) (Lot no. LFA 015071) and TNFR2 (PE) (Lot no. LFB 046021), used
for flow cytometry, were obtained from R&D systems (Minneapolis, MN, USA). Fas
(CD95) antibody (BD Biosciences; Lot no. 29991) was used for detection of Fas by
flow cytometry. Recombinant anti-human Fas monoclonal antibody (FAS10) was
obtained from the CLB Sanquin Blood Foundation (CLB, Amsterdam, The
Netherlands). The production and characterization of CysTNF32W/86T, referred to
as TNFa-TNFR1, and CysTNF143N/145R, referred to as TNFa-TNFR2, has been
described elsewhere.51,52 CHX, bafilomycin A and ammonium chloride were
purchased from Sigma-Aldrich (St. Louis, MO, USA). MG132 was obtained from
Calbiochem/Merck Millipore, Billerica, MA, USA). The pan-caspase inhibitor QVD
was from R&D systems (Minneapolis, MN, USA).
Cell culture and stimulations. Control (3T3 fibroblast cell line (3T3)) and
human CD40L stably transfected (CD40L-expressing 3T3 cell (3T40)) NIH3T3
feeder cells were cultured in Iscove’s modified Dulbecco’s medium (IMDM; Gibco
Life Technology, Paisley, FL, USA) supplemented with 10% FCS, 100 U/ml
penicillin, 100mg/ml gentamycin and 0.00036% b-mercaptoethanol. PB lympho-
cytes of CLL patients were co-cultured with control 3T3 cells or CD40L-expressing
3T3 cells, as described previously.2 Briefly, DMSO-frozen CLL cells were thawed
and co-cultured on irradiated (30 Gy) control or CD40L-expressing 3T3 cells. The
final CLL cell concentration was 1.67 106 cells/ml in IMDM. Kym-1 cells were
cultured in RPMI medium (Gibco Life Technology) supplemented with 10% FCS,
100 U/ml penicillin, 100 mg/ml gentamycin and 0.00036% b-mercaptoethanol.
Stimulations of CLL cells with Compound A, alone or in combination with other
reagents, were performed simultaneously with the incubation on 3T3 or 3T40 cells.
For the caspase-8 IP experiment, CLL cells were collected after co-culturing on
3T40 cells, to be treated with Compound A in a new cell culture dish.
Apoptosis assays. Apoptosis levels were determined with annexin V-APC
(IQ Products, Groningen, The Netherlands) and propidium iodide (PI) staining
(Sigma, St. Louis, MO, USA) or 3,30-dihexyloxacarbocyanine iodide (DioC6;
Invitrogen) and PI and flow cytometry.2
Western blot and antibodies. Western blotting was performed as
described previously.2 Samples (30–60mg protein) were separated by 7.5–13%
sodium dodecyl sulfate polyacrylamide gel electrophoresis. The caspase-8 (clone
C-20, no. sc-6136) IP antibody was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Blots were probed with polyclonal NF-kB2 p100/p52
(no. 4882; Cell Signaling, Beverly, MA, USA), monoclonal mouse antibody for p-IkBa
(no. 9246, Cell Signaling), NIK (no. 4994; Cell Signaling), TRAF2 (no. sc-876;
Santa Cruz Biotechnology), TRAF6 (no. 4743s; Cell Signaling), caspase-8 (clone
5F7, no. M032-3; MBL, Woburn MA, USA), RIPK1 (no. 610458; BD Biosciences),
rat polyclonal antibodies against cIAP1 and cIAP2 (La Trobe University,
Melbourne, Australia) and antiserum to actin (clone I-19, no. sc-1616; Santa
Cruz Biotechnology). IRDye 680 donkey anti-rat IgG, IRDye 680 donkey anti-rabbit
IgG, IRDye 800 donkey anti-goat IgG or IRDye 800 donkey anti-mouse IgG
(Westburg, Leusden, The Netherlands) was used as secondary antibody.
Western blots were scanned on the Odyssey imager (LI-COR Biosciences,
Lincoln, NE, USA).
Enzyme-linked immunosorbent assay. For the determination of TNFa
protein levels, PB lymphocytes of CLL patients were co-cultured with 3T40 cells
(as described above), supernatant was collected and TNFa levels were measured
using the PeliKine human enzyme-linked immunosorbent assay (ELISA) kit (Sanquin,
Amsterdam, The Netherlands) according to the manufacturer’s recommendations.
Activity of active NF-kB subunits p65 and p52 was also measured using ELISA,
using the TransAM NF-kB family transcription factor assay kit (Active Motif, La Hulpe,
Belgium), according to the manufacturer’s instructions.
RNA isolation and reverse transcription–multiplex ligation-
dependent probe amplification assay. Total RNA was isolated using
the GenElute Mammalian Total RNA Miniprep Kit (Sigma-Aldrich). Reverse
transcription–multiplex ligation-dependent probe amplification assay (RT-MLPA)
procedure was performed as described previously.29,53 Only the mRNA levels of
NF-kB target genes are shown. Equal amounts of mRNA were included per
reaction, and all samples were tested in a single experiment using the same batch
of reagents. Relative mRNA expression of the gene of interest is calculated by
setting the total signal for each sample at 100%, and individual signals of genes of
interest were calculated relative to the 100% value.
Statistical analysis. The Shapiro–Wilk normality test was performed to
analyze Gaussian distributions. If there was a Gaussian distribution, a two-sided
t-test was used to analyze differences between the groups. If there was no
Gaussian distribution, a two-tailed Mann–Whitney U-test was used to analyze
differences between the groups, and a Wilcoxon matched paired test was used to
analyze differences between paired samples. Statistically significance of the data
was set at Po0.05, with one asterisk (*) representing 0.01o Po0.05; two
asterisks (**) representing 0.001oPo0.01; and three asterisks(***) representing
Po0.001.
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